Assessment of the Direct Medical Costs of Diabetes Mellitus and Its Complications in the United Arab Emirates

Overview

Journal BMC Public Health

Publisher Biomed Central

Specialty Public Health

Date 2010 Nov 10

PMID 21059202

Citations 51

Authors

Fatma Al-Maskari

Mohammed El-Sadig

Nicholas Nagelkerke

Affiliations

Soon will be listed here.

Abstract

Background: Diabetes mellitus (DM) is a major health problem in the United Arab Emirates (UAE) and is well recognized as a major and increasing burden to the country's resources due to its severe, long term debilitating effects on individuals, families and the society at large. The aim of the study was to estimate the direct annual treatment costs of DM and its related complications among patients in Al-Ain city, UAE.

Methods: A sample of 150 DM patients were enrolled during 2004-2005, and their medical costs over the ensuing 12 months was measured, quantified, analyzed and extrapolated to the population in Al-Ain and UAE, using conventional and inference statistics. The costs were converted from UAE Dirhams to US Dollar, using the official conversion rate of US$ (1 USD = 3.68 AED).

Results: The total annual direct treatment costs of DM among patients without complications in Al Ain-UAE, was US $1,605 (SD = 1,206) which is 3.2 times higher than the per capita expenditure for health care in the UAE (US$ 497) during 2004 (WHO, 2004). However, this cost increased 2.2 times with the presence of DM related complications for patients with microvascular complications, by 6.4 times for patients with macrovascular complications and 9.4 times for patients with both micro and macrovascular complications. Likewise, the annual direct hospitalization costs of DM patients increased by 3.7 times for patients with microvascular complications, by 6.6 times for patients with macrovascular complications and by 5 times for patients with both micro and macrovascualr complications. Overall, costs increased with age, diabetes duration and were higher for patients treated with insulin compared to those treated with oral hypoglycemic agents or with diet control only.

Conclusions: DM direct treatment costs increased with the presence and progression of chronic DM related complications. Hospitalisation costs constituted a large proportion and were increasingly higher with the presence and progression of DM related complications. To reduce the impact on healthcare resources, efforts should be made to prevent progression to DM complications, by implementing guidelines for diabetes care, screening for complications and better management.

Citing Articles

Association between night shift work and the risk of type 2 diabetes mellitus: a cohort-based meta-analysis.

Xie F, Hu K, Fu R, Zhang Y, Xiao K, Tu J BMC Endocr Disord. 2024; 24(1):268.

PMID: 39696306 PMC: 11653577. DOI: 10.1186/s12902-024-01808-w.

Depression and Anxiety Screening of Patients With Type II Diabetes Mellitus Attending Primary Healthcare Centers in Saudi Arabia.

Aldebani M, Saigh A, Aljifri A, Hariri N Cureus. 2024; 16(9):e69393.

PMID: 39403648 PMC: 11472354. DOI: 10.7759/cureus.69393.

Burden of non-communicable diseases in Health Council of Gulf Cooperation (GCC) countries.

Alqadasi E, Chamroonsawasdi K, Saejeng K, Nagi M J Taibah Univ Med Sci. 2024; 19(4):877-884.

PMID: 39247447 PMC: 11380384. DOI: 10.1016/j.jtumed.2024.07.009.

Healthcare Utilization and Discrepancies by Income Level Among Patients With Newly Diagnosed Type 2 Diabetes in Korea: An Analysis of National Health Insurance Sample Cohort Data.

Park E, Ji N, You C, Lee W J Prev Med Public Health. 2024; 57(5):471-479.

PMID: 39164109 PMC: 11471334. DOI: 10.3961/jpmph.24.165.

Association Between the Hepatic Steatosis Index and Risk of Incident Type 2 Diabetes Mellitus in the Normoglycemic Population:A Longitudinal Prospective Study in Japan.

Si R, Xiao J, Zheng K, Yin Y, Li Y Diabetes Metab Syndr Obes. 2024; 17:2317-2326.

PMID: 38863519 PMC: 11166155. DOI: 10.2147/DMSO.S462459.

References

. Economic costs of diabetes in the U.S. In 2007. Diabetes Care. 2008; 31(3):596-615. DOI: 10.2337/dc08-9017. View

Ettaro L, Songer T, Zhang P, Engelgau M . Cost-of-illness studies in diabetes mellitus. Pharmacoeconomics. 2004; 22(3):149-64. DOI: 10.2165/00019053-200422030-00002. View

Esteghamati A, Khalilzadeh O, Anvari M, Meysamie A, Abbasi M, Forouzanfar M . The economic costs of diabetes: a population-based study in Tehran, Iran. Diabetologia. 2009; 52(8):1520-7. DOI: 10.1007/s00125-009-1398-4. View

Jonsson B . The economic impact of diabetes. Diabetes Care. 1998; 21 Suppl 3:C7-10. DOI: 10.2337/diacare.21.3.c7. View

Henriksson F, Agardh C, Berne C, Bolinder J, Lonnqvist F, Stenstrom P . Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med. 2000; 248(5):387-96. DOI: 10.1046/j.1365-2796.2000.00749.x. View

Barcelo A, Aedo C, Rajpathak S, Robles S . The cost of diabetes in Latin America and the Caribbean. Bull World Health Organ. 2003; 81(1):19-27. PMC: 2572319. View

Al-Maskari F, El-Sadig M, Norman J . The prevalence of macrovascular complications among diabetic patients in the United Arab Emirates. Cardiovasc Diabetol. 2007; 6:24. PMC: 2093928. DOI: 10.1186/1475-2840-6-24. View

Brown J, Nichols G, Glauber H, Bakst A, Schaeffer M, Kelleher C . Health care costs associated with escalation of drug treatment in type 2 diabetes mellitus. Am J Health Syst Pharm. 2001; 58(2):151-7. DOI: 10.1093/ajhp/58.2.151. View

Koster I, von Ferber L, Ihle P, Schubert I, Hauner H . The cost burden of diabetes mellitus: the evidence from Germany--the CoDiM study. Diabetologia. 2006; 49(7):1498-504. DOI: 10.1007/s00125-006-0277-5. View

10.

Marchesini G, Forlani G, Rossi E, Berti A, de Rosa M . The direct economic cost of pharmacologically-treated diabetes in Italy-2006. The ARNO observatory. Nutr Metab Cardiovasc Dis. 2010; 21(5):339-46. DOI: 10.1016/j.numecd.2009.10.009. View

11.

Malik M, Bakir A, Saab B, Roglic G, King H . Glucose intolerance and associated factors in the multi-ethnic population of the United Arab Emirates: results of a national survey. Diabetes Res Clin Pract. 2005; 69(2):188-95. DOI: 10.1016/j.diabres.2004.12.005. View

12.

Jonsson B . Revealing the cost of Type II diabetes in Europe. Diabetologia. 2002; 45(7):S5-12. DOI: 10.1007/s00125-002-0858-x. View

13.

Khowaja L, Khuwaja A, Cosgrove P . Cost of diabetes care in out-patient clinics of Karachi, Pakistan. BMC Health Serv Res. 2007; 7:189. PMC: 2206019. DOI: 10.1186/1472-6963-7-189. View

14.

Elrayah-Eliadarous H, Yassin K, Eltom M, Abdelrahman S, Wahlstrom R, Ostenson C . Direct costs for care and glycaemic control in patients with type 2 diabetes in Sudan. Exp Clin Endocrinol Diabetes. 2010; 118(4):220-5. DOI: 10.1055/s-0029-1246216. View

15.

Rekik M, Abid M, Hachicha J, Abbes R, Moujahed M, Jarraya A . [Direct cost of the ambulatory management of diabetes at the outpatient clinic of the National Social Security Fund of Sfax (Tunisia)]. Bull World Health Organ. 1994; 72(4):611-4. PMC: 2486610. View

16.

Arab M . Diabetes mellitus in Egypt. World Health Stat Q. 1992; 45(4):334-7. View

17.

Al-Maskari F, El-Sadig M . Prevalence of diabetic retinopathy in the United Arab Emirates: a cross-sectional survey. BMC Ophthalmol. 2007; 7:11. PMC: 1913498. DOI: 10.1186/1471-2415-7-11. View

18.

MUSHKIN S, COLLINGS F . Economic costs of disease and injury. Public Health Rep (1896). 1959; 74:795-809. PMC: 1929317. View